Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11174631 | 0.94 | CYP19A1 (0.43) | POLBBLMKMT2AMEN1NSD2 | |
| SCHEMBL4198995 | 0.78 | MEN1 (0.37) | POLBBLMKMT2AMEN1NSD2 | |
| SCHEMBL6441137 | 0.74 | SLC18A3 (0.41) | POLBBLMKMT2AKDM4EALDH1A1 | |
| SCHEMBL11178298 | 0.73 | CYP19A1 (0.44) | POLBBLMKMT2AMEN1NSD2 | |
| SCHEMBL6445634 | 0.71 | SIGMAR1 (0.39) | POLBBLMKDM4EALDH1A1TDP1 | |
| SCHEMBL4191462 | 0.71 | NQO1 (0.38) | POLBBLMKMT2AMEN1NSD2 | |
| SCHEMBL11171014 | 0.71 | CYP19A1 (0.43) | POLBBLMKMT2AMEN1NSD2 | |
| SCHEMBL4187451 | 0.69 | CYP19A1 (0.35) | POLBBLMKMT2AMEN1NSD2 | |
| SCHEMBL4190666 | 0.68 | KMT2A (0.32) | POLBBLMKMT2AMEN1NSD2 | |
| SCHEMBL11177829 | 0.67 | CYP19A1 (0.48) | POLBBLMKMT2AMEN1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156807-A1 | Anti-tumor Compounds Derived From 1,4,5,8-tetrachloroanthraquinone | ISHMAEL D RICHARD | 2009-06-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156807-A1 | Anti-tumor Compounds Derived From 1,4,5,8-tetrachloroanthraquinone | CASP4, CASP8, CASP1 | POLB 2943/4885BLM 2631/4885KMT2A 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.